[4] He spent two years at the National Institute of Environmental Health Sciences (NIEHS) before joining the faculty of the Department of Biochemistry and Cell Biology and the School of Medicine at Stony Brook University in 1982.
[7] In collaboration with Margaret Kidwell, then at Brown University, and Gerry Rubin, then at the Carnegie Institution, he carried out the molecular cloning of the P element transposon in Drosophila.
[4][18] Bingham and Zachar discovered the first-in-class anti-cancer mitochondrial metabolism drug (CPI-613; devimistat),[19] currently in Phase III registrational clinical trials in pancreatic ductal adenocarcinoma and acute myeloid leukemia.
It proposed to account for the evolution of the human species from the advent of its phylogenetic branching from other hominins through physiological and behavioral adaptations until our current civilization.
[26] According to his theory, the cost to an enforcer of coercing a cheating individual into a cooperative effort, known as the free-rider problem, was lowered when a precursor species to humans developed a way to threaten adult conspecifics from a distance by evolving the ability to throw projectiles with sufficient skill to reliably injure the cheater, especially conjointly with others.
[28] The theory proposes that this elite throwing ability initially allowed bands of proto-humans improved capacity to repel predators and scavenge their kills in the African savanna.
Bingham also serves on the management team of Rafael Pharmaceuticals, a firm developing cancer therapies, as Vice President of Research.